Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Authors:
- Marie-Julie NokinMNMarie-Julie Nokin
- Elodie DarboEDElodie Darbo
- Camille TravertCTCamille Travert
- Benjamin DrogatBDBenjamin Drogat
- Aurélie LacoutureALAurélie Lacouture
- Sonia San JoséSJSonia San José
- Nuria CabreraNCNuria Cabrera
- Béatrice TurcqBTBéatrice Turcq
- Mattia FalconeMFMattia Falcone
- Alberto VillanuevaAVAlberto Villanueva
- Haiyun WangHWHaiyun Wang
- 6 August 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (15)
Abstract
Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient stratification and for the identification of new therapeutic strategies, including enhancing the efficacy of chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) may be both a predictive factor for chemoresistance in patients with LUAD and a potential target positively selected in resistant cells. By using biopsies from patients with LUAD, KRAS-mutant LUAD cell lines, and in vivo genetically engineered KRAS-driven mouse models, we evaluated the role of DDR1 in the context of chemotherapy treatment. We found that DDR1 is upregulated during chemotherapy both in vitro and in vivo. Moreover, analysis of a cohort of patients with LUAD suggested that high DDR1 levels in pretreatment biopsies correlated with poor response to chemotherapy. Additionally, we showed that combining DDR1 inhibition with chemotherapy prompted a synergistic therapeutic effect and enhanced cell death of KRAS-mutant tumors in vivo. Collectively, this study suggests a potential role for DDR1 as both a predictive and prognostic biomarker, potentially improving the chemotherapy response of patients with LUAD.Keywords
Funding Information
- Fondation ARC pour la recherche contre le cancer (PJA 20161204784)
- Région Nouvelle Aquitaine (2017-1R30212)
- SIRIC-BRIO (2018)
- Giovanni Armenise–Harvard Foundation (CDA Start-Up 2018)
- Lung Cancer Research Foundation (Research Grant 2018)
- Spanish Association Against Cancer (Modalidad A Investigación)
- Bourse d’excellence de la Fédération Wallonie-Bruxelles (Postdoc fellowship)
- Acció instrumental d’intensificació de professionals de la salut (SLT006/17/00127)
- CERCA Program / Generalitat de Catalunya (2017SGR448)
- Senior Chair Idex-Université de Bordeaux (2016-0396)
This publication has 49 references indexed in Scilit:
- Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transitionMedical Oncology, 2013
- KRAS Mutation: Should We Test for It, and Does It Matter?Journal of Clinical Oncology, 2013
- Discoidin domain receptor tyrosine kinases: new players in cancer progressionCancer and Metastasis Reviews, 2012
- Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone MetastasisClinical Cancer Research, 2012
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung CarcinomaCancer Cell, 2011
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung CarcinomaCancer Cell, 2010
- Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerGenes & Development, 2010
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- K‐ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatmentCancer Science, 2007
- Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian CancerClinical Cancer Research, 2004